The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $35.66

Today's change+0.39 +1.11%
Updated December 8 2:48 PM EST. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $35.66

Today's change+0.39 +1.11%
Updated December 8 2:48 PM EST. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd up (U.S.)$0.39

Teva Pharmaceutical Industries Ltd is up today by (U.S.)$0.39 or 1.11% to (U.S.)$35.66. Over the last five days, shares have lost 2.49% and sit 3.15% above their 52-week low. This security has underperformed the S&P 500 by 54.45% during the last year.

Key company metrics

  • Open(U.S.) $35.40
  • Previous close(U.S.) $35.27
  • High(U.S.) $36.48
  • Low(U.S.) $35.22
  • Bid / Ask(U.S.) $35.66 / (U.S.) $35.67
  • YTD % change-45.67%
  • Volume9,161,073
  • Average volume (10-day)9,157,447
  • Average volume (1-month)12,259,988
  • Average volume (3-month)8,626,051
  • 52-week range(U.S.) $34.57 to (U.S.) $66.55
  • Beta0.67
  • Trailing P/E20.60×
  • P/E 1 year forward6.86×
  • Forward PEG1.93×
  • Indicated annual dividend(U.S.) $1.36
  • Dividend yield3.81%
  • Trailing EPS(U.S.) $1.73
Updated December 8 2:48 PM EST. Delayed by at least 15 minutes.
S&P TSX0.32%Sector:Industry:

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue5,5635,0384,8104,881
Total other revenue--------
Total revenue5,5635,0384,8104,881
Gross profit2,8012,8772,7912,847
Total cost of revenue2,7622,1612,0192,034
Total operating expense4,7984,6773,6453,950
Selling / general / administrative1,2501,2631,1431,207
Research & development663375389446
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)72079231192
Other operating expenses, total-597866371
Operating income7653611,165931
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax615256867861
Income after tax408227639612
Income tax, total20729228249
Net income412254636500
Total adjustments to net income-64-66-66-15
Net income before extra. items412254636500
Minority interest21232
Equity in affiliates215-6-114
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items348188570485
Inc. avail. to common incl. extra. items348188570485
Diluted net income348188570485
Dilution adjustment0000
Diluted weighted average shares984920920876
Diluted EPS excluding extraordinary itemsvalue per share0.350.200.620.55
Dividends per sharevalue per share0.340.340.340.34
Diluted normalized EPSvalue per share0.840.970.640.71